Evidence map›Paper›PMID 38478331›Full record

SynthesisDrugs2024

Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials.

Yifan Wang, He Yi, Weixia Sun, Hekai Yu, Wenxuan Tao, Xiaojin Yu, Dianrong Jia, Yingzhao Liu, Stephen J Pandol, Ling Li

Abstract readComparative StudySystematic ReviewNetwork Meta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Yifan Wang *Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
He Yi *Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
Weixia Sun *Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
Hekai YuDepartment of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
Wenxuan TaoDepartment of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
Xiaojin YuDepartment of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing, 210009, China.
Dianrong JiaDepartment of Endocrinology, Taizhou Jiangyan Hospital of Traditional Chinese Medicine, Taizhou, 225500, China.
Yingzhao LiuDepartment of Endocrinology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, 212000, China.
Stephen J PandolDivision of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Ling LiDepartment of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. lingli@seu.edu.cn.ORCID http://orcid.org/0000-0003-0083-6978
Zhongda Hospital Southeast University · CNAnyang Hospital of Traditional Chinese Medicine · CNCedars-Sinai Medical Center · USJiangsu University · CNSoutheast University · CNSoutheast University · BD

Funding

Jiangsu Provincial Key Research and Development Program No.BE2022853Major International Joint Research Programme 82320108003Medical Key Discipline of Jiangsu Province ZDXK202203National Natural Science Foundation of China 81970717National Natural Science Foundation of China 82000740National Natural Science Foundation of China 82170845
6 · The paper itself

Abstract

BACKGROUND AND

aimsNonalcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), affects approximately 38% of the world's population, yet no pharmacological therapies have been approved for treatment. We conducted a traditional and network meta-analysis to comprehensively assess the effectiveness of drug regimens on NAFLD, and continued to use the old terminology for consistency.

methodsRandomized, placebo-controlled trials (RCTs) investigating drug therapy in an adult population diagnosed with NAFLD with or without diabetes mellitus were included. We assessed the quality of RCTs via the Risk of Bias 2 (ROB 2) tool. When I

resultsThiazolidinediones (TZDs), vitamin E plus pioglitazone, glucagon-like peptide-1 (GLP-1) receptor agonists and fibroblast growth factor-21 (FGF-21) analogue had a higher surface under the cumulative ranking curve (SUCRA = 76.6, 73.0, 72.0 and 71.6) regarding NASH resolution. Improvement of liver fibrosis stage (≥ 1) was observed with obeticholic acid 25 mg/day (OR 2.01, 95% CI 1.35-2.98), lanifibranor 1200 mg/day (OR 2.39, 95% CI 1.19-4.82) and silymarin (OR 4.54, 95% CI 1.18-17.43) in traditional meta-analysis.

conclusionsThe results of the comprehensive analysis suggested hypoglycemic drug therapy as an effective intervention for NAFLD, with or without diabetes mellitus. A prioritized selection of TZDs, vitamin E plus pioglitazone, GLP-1 receptor agonists and FGF-21 analogue may be considered for NASH resolution. Obeticholic acid, lanifibranor and silymarin could be considered for the improvement of liver fibrosis. Each medication was relatively safe compared with placebo.

Indexed as

Non-alcoholic Fatty Liver DiseaseChenodeoxycholic AcidFibroblast Growth FactorsHumansRandomized Controlled Trials as TopicTreatment OutcomeChenodeoxycholic Acidfibroblast growth factor 21Fibroblast Growth Factorsobeticholic acid

Identifiers

PMID38478331
OpenAlexW4392751953

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.